Treatment of nail psoriasis with calcipotriol/betamethasone dipropionate foam versus pulse dye laser: an unblinded, intra‐patient, left‐to‐right prospective study

Gregoriou, Stamatis; Sidiropoulou, Polytimi; Tsimpidakis, Antonios; Rompoti, Natalia; Tsironi, Theodora; Panagakis, Pantelis; Polydorou, Dorothea; Kostakis, Panagiotis; Rigopoulos, Dimitrios

doi:10.1111/jdv.16426

Cited by 13 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cal/BD in foam formulation for the treatment of nail psoriasis demonstrated it was welltolerated and lacked steroid-related adverse reactions, but larger clinical trials are underway to better establish its efficacy and tolerability for this indication. 11 Our case series demonstrates the potential of Cal/BD aerosol foam as a treatment for nail psoriasis. This can be a desirable option for patients with contraindications to systemic therapy or a preference for topical therapy in a foam vehicle.…”

Section: Discussionmentioning

confidence: 75%

Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam as a Treatment for Nail Psoriasis

et al. 2021

View full text Add to dashboard Cite

Combination topical corticosteroids and vitamin D analog treatments for nail psoriasis are widely used in cream and ointment vehicles, but patients may prefer a foam vehicle due to ease of application and favorable cosmetic appearance. Calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) aerosol foam is an FDA approved therapy for plaque psoriasis, but may also be an effective treatment for nail psoriasis in a novel aerosol foam. We present a case series of 3 patients with mild to moderate nail psoriasis who responded positively to treatment with Cal/BD aerosol foam applied 1-2 times daily to affected nails for at least 6 weeks. Reduction of nail plate surface abnormalities and a decrease in inflammation of the nail folds were assessed with clinical evaluation and dermoscopy, and documented with serial photography. While further research on the efficacy and safety of Cal/BD aerosol foam as a treatment for nail psoriasis is needed, this report suggests its potential as a combination topical vitamin D analogue and high potency steroid in a foam vehicle.

show abstract

Section: Discussionmentioning

confidence: 75%

Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam as a Treatment for Nail Psoriasis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…(c) In patients with nail psoriasis, there is an additional and cumulative conditional strength recommendation (*) for the use of topical combination calcipotriol/betamethasone dipropionate. 5,6 (d) In patients with nail psoriasis, there is an additional and cumulative conditional strength recommendation (*) for the use of topical tacrolimus. 7 (e) In patients with nail psoriasis, there is insufficient additional evidence (X) to make a recommendation for the use of topical cyclosporine (no eligible literature to comment on or reference).…”

Section: Resultsmentioning

confidence: 99%

Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

et al. 2022

View full text Add to dashboard Cite

ObjectiveNail psoriasis is common, impairs fine motor finger functioning, affects cosmesis, and is associated with a lower quality of life. This review updates the previous Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for nail psoriasis.MethodsThis systematic literature review of the PubMed, MEDLINE, Embase, and Cochrane databases examined the updated evidence since the last GRAPPA nail psoriasis treatment recommendations published in 2014. Recommendations are based on preformed PICO (Patient/Population - Intervention - Comparison/Comparator - Outcome) questions formulated by an international group of dermatologists, rheumatologists, and patient panel members. Data from this literature review were evaluated in line with Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology.ResultsOverall, there is insufficient evidence to make any recommendation for the use of topical corticosteroids, topical calcipotriol, topical tazarotene, topical cyclosporine, dimethyl fumarates/fumaric acid esters, phototherapy, and alitretinoin. There is a low strength of evidence to support the use of calcipotriol and corticosteroid preparations, topical tacrolimus, oral cyclosporine, oral methotrexate, intralesional corticosteroids, pulsed dye laser, acitretin, Janus kinase inhibitors, and apremilast.ConclusionThe highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.

show abstract

“…Recently, Gregoriou et al performed an intra-patient (left vs. right) prospective study in 20 patients with the aim to compare the efficacy of calcipotriol/betamethasone dipropionate (Cal/BD) foam with PDL for nail psoriasis over 12 weeks [68]. The mean total NAPSI score in the Cal/BD-treated nails was reduced from 7.85 (week 0) to 4.4 at week 12 (p \ 0.0001).…”

Section: Laser Therapiesmentioning

confidence: 99%

Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management

Hadeler

Mosca

Hong

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Nail psoriasis has a prevalence that ranges from 10 to 82% and can significantly impact the quality of life of patients. Nail psoriasis is one of the most challenging areas to treat, and multiple therapies have been explored. Topical and injectable therapies are recommended for fewnail disease. Systemic therapies, including biologics, can be considered for patients with multiple and resistant nail disease, impaired quality of life, and severe skin and joint involvement, due to their long-term efficacy. Although outcome data are difficult to compare, interleukin (IL)-17 inhibitors may have superior short-term efficacy when compared to IL-23 inhibitors and tumor necrosis factor (TNF)-alpha inhibitors, although long-term efficacy is similar to TNF-alpha inhibitors. IL-23 inhibitors and TNF-alpha inhibitors have a similar efficacy for nail psoriasis.

show abstract

Treatment of nail psoriasis with calcipotriol/betamethasone dipropionate foam versus pulse dye laser: an unblinded, intra‐patient, left‐to‐right prospective study

Cited by 13 publications

References 10 publications

Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam as a Treatment for Nail Psoriasis

Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam as a Treatment for Nail Psoriasis

Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management

Contact Info

Product

Resources

About